Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)

Fig. 3

a. Incidence of peripheral sensory neuropathy. The cumulative peripheral sensory neuropathy rate was 63.5%, including 3.8% of patients with grade 3. The frequencies of PNS after 4 cycles of initial CapeOX plus bevacizumab therapy and 8 cycles of the maintenance therapy with capecitabin plus bevacizumab were 42 and 9%, respectively. CapeOX, capecitabin and oxaliplatin; BEV, bevacizumab; N, total number of patients. b. Incidence of hand-foot syndrome. The frequencies of hand-foot syndrome were 63.5% in induction therapy, 48.9% in maintenance therapy, and 55.2% in reintroduced therapy. CapeOX, capecitabin and oxaliplatin; BEV, bevacizumab; N, total number of patients. c. Incidence of bevacizumab-related toxicities. The frequencies of bevacizumab-related toxicities were 26.9% in induction therapy, 37.8% in maintenance therapy, and 37.9% in reintroduced therapy. CapeOX, capecitabin and oxaliplatin; BEV, bevacizumab; N, total number of patients

Back to article page